UCART-22 is a gene-modified cell therapy commercialized by Cellectis, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of UCART-22’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for UCART-22 is expected to reach an annual total of $37 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
UCART-22 Overview
UCART-22 is under development for the treatment of relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia. The drug candidate is an allogeneic gene-edited T-cell product candidate. It is an immunotherapy comprising of CAR T cells and acts by targeting CD22. It is administered through intravenous route.
It was also under development for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and B-cell non-Hodgkin lymphoma (B-NHL).
Cellectis Overview
Cellectis, operates as a clinical-stage biopharmaceutical company. The company’s pipeline products include UCART22 is for the treatment of acute lymphoblastic leukemia; UCART123 targets acute myeloid leukemia; UCART20x22 treats non hodgkin lymphoma; cemacabtagene ansegedleucel for large b cell lymphoma, chronic lymphocytic leukemia; ALLO-715, ALLO-605 are for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma. It works in partnership with Allogene Therapeutics, Servier, Iovance Biotherapeutics, Inc, Cytovia Therapeutics, Inc. It operates in New York and Paris. Cellectis is headquartered in Paris, France.
The company reported revenues of (US Dollars) US$9.2 million for the fiscal year ended December 2023 (FY2023), a decrease of 64.3% over FY2022. The operating loss of the company was US$97.3 million in FY2023, compared to an operating loss of US$89.7 million in FY2022. The net loss of the company was US$101.1 million in FY2023, compared to a net loss of US$106.1 million in FY2022.
For a complete picture of UCART-22’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.